Why it expresses the thesis
The purest public expression of the data-moat argument: 200+ petabytes of multimodal oncology data, relationships with a large share of US oncologists, and a recently-hit positive adjusted-EBITDA inflection on $1.27B revenue growing ~25–30%. Management positions it as AI infrastructure, not a diagnostics vendor — exactly the durable layer the thesis overweights.
The data asset is closed-loop: genetic sequencing, clinical records, and medical imaging combined into a dataset that compounds with every patient and cannot be scraped or bought. That scale is the barrier to entry.
The higher-margin mix
The Lens analytics platform and AI-driven trial-matching technologies serve pharmaceutical clients. These higher-margin offerings — not the base diagnostics — are the segments carrying the multiple and attracting investor attention. Recent oncology partnerships (Merck, Predicta Biosciences) reinforce the precision-medicine flywheel.
What to diligence
- Path to GAAP profitability and cash burn trajectory.
- Defensibility of the data moat against payer/provider data-portability mandates.
- Concentration in oncology versus expansion into cardiology and neuropsychiatry.
- Whether the Lens / trial-matching higher-margin mix can sustain the forward multiple.
Current technicals are weak and the stock has pulled back year-to-date — a position to scale into on volatility rather than chase.